Keryx at UBS Warburg Global Life Sciences Conference

    Keryx Biopharmaceuticals to Present at UBS Warburg Global Life Sciences 
                                  Conference 
 
    NEW YORK, Sept. 18 -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX; London 
AIM: KRX) a biopharmaceutical company focused on the acquisition, development 
and commercialization of novel pharmaceutical products for the treatment of 
life-threatening diseases, including diabetes and cancer, announced today that 
Michael S. Weiss, Chairman and Chief Executive Officer, will present an overview 
of the Company's strategic plans and recent developments at the UBS Warburg 
Global Life Sciences Conference in New York City.  Mr. Weiss's presentation will 
take place on Tuesday, September 23, 2003, at 12:00 pm EST, in the Le Louvre 
Room of the Plaza Hotel. A live audio webcast will be available during the 
presentation via the UBS homepage at www.ibb.ubs.com.  To access the webcast, 
click on "Conferences" in the middle of the page and follow the link for Webcast 
under the Global Life Sciences Conference heading.  An archive of the webcast 
will be available beginning 3 hours after the live presentation and will be 
available until October 25, 2003.   
 
    About Keryx Biopharmaceuticals, Inc.  
    Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX; London AIM: KRX) is a 
biopharmaceuticals company focused on the acquisition, development and 
commercialization of novel pharmaceutical products for the treatment of  
life-threatening diseases, including diabetes and cancer. Keryx is developing 
KRX-101 (sulodexide), a novel first-in-class oral heparinoid compound, for the 
treatment of diabetic nephropathy, for which Keryx is currently planning its 
U.S.-based Phase II/III clinical program.  Keryx also has an active  
in-licensing program designed to identify and acquire clinical-stage drug 
candidates.  Additionally, Keryx is seeking partners for its KinAce(TM) drug 
discovery technology and related products.  Keryx Biopharmaceuticals is 
headquartered in New York City.  
   
     KERYX CONTACT: 
 
     Ron Bentsur                                       Thomas Redington 
     Vice President, Finance & Investor Relations      Redington, Inc. 
     Keryx Biopharmaceuticals, Inc.                    203.222.7399 
     212.531.5965                                      212.926.1733 
     [e-mail]                                     [e-mail] 
 
SOURCE  Keryx Biopharmaceuticals, Inc. 
    -0-                             09/18/2003 
    /CONTACT:  Ron Bentsur, Vice President, Finance & Investor Relations of 
Keryx Biopharmaceuticals, Inc., [phone], [e-mail]; or Thomas 
Redington of Redington, Inc., [phone], or [phone], 
[e-mail], for Keryx Biopharmaceuticals, Inc./ 
    /Web site:  http://www.ibb.ubs.com / 
    (KERX) 
 





END